Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in ewing sarcoma: A report from the children's oncology group

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 1989-1994

  Van Doorninck, John A ^a   Ji, Lingyun ^a   Schaub, Betty ^a   Shimada, Hiroyuki ^a   Wing, Michele R ^a   Krailo, Mark D ^a   Lessnick, Stephen L ^a   Marina, Neyssa ^a   Triche, Timothy J ^a   Sposto, Richard ^a   Womer, Richard B ^a   Lawlor, Elizabeth R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; EWS ERG FUSION PROTEIN, HUMAN; EWS FLI1 FUSION PROTEIN; EWS-ERG FUSION PROTEIN, HUMAN; EWS-FLI1 FUSION PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI 1;

ADOLESCENT; ADULT; ARTICLE; CHILD; EVENT FREE SURVIVAL; EWING SARCOMA; EWS FLI1 GENE; FEMALE; FUSION GENE; GENE FUSION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; BIOPSY; BONE TUMOR; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; INFANT; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEIN C-FLI-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; SARCOMA, EWING'S; TIME FACTORS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77951644822     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.5845     Document Type: Article

References (23)

1. Bernstein M, Kovar H, Paulussen M, et al: Ewing's sarcoma family of tumors: Ewing sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 5). Philadelphia, PA, Lippincott Williams & Wilkins, 2006, pp 1002-1032
2. Rodríguez-Galindo C, Liu T, Krasin MJ, et al: Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies. Cancer 110:375-384, 2007
3. Rodriguez-Galindo C, Spunt SL, Pappo AS: Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Med Pediatr Oncol 40:276-287, 2003 (Pubitemid 36397630)
4. Jenkin RD, Al-Fawaz I, Al-Shabanah M, et al: Localised Ewing sarcoma/PNET of bone: Prognostic factors and international data comparison. Med Pediatr Oncol 39:586-593, 2002 (Pubitemid 35191442)
5. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003 (Pubitemid 36237038)
6. Ahrens S, Hoffmann C, Jabar S, et al: Evaluation of prognostic factors in a tumor volumeadapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience - Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 32:186-195, 1999 (Pubitemid 29095978)
7. Paulussen M, Ahrens S, Dunst J, et al: Localized Ewing tumor of bone: Final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19:1818-1829, 2001
8. Bacci G, Ferrari S, Longhi A, et al: Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep 6:807-811, 1999
9. Hattinger CM, Potschger U, Tarkkanen M, et al: Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 86:1763-1769, 2002 (Pubitemid 34712921)
10. Wei G, Antonescu CR, de Alava E, et al: Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89:793-799, 2000 (Pubitemid 30658578)
11. Abudu A, Mangham DC, Reynolds GM, et al: Overexpression of p53 protein in primary Ewing's sarcoma of bone: Relationship to tumour stage, response and prognosis. Br J Cancer 79:1185-1189, 1999 (Pubitemid 29087896)
12. de Alava E, Antonescu CR, Panizo A, et al: Prognostic impact of P53 status in Ewing sarcoma. Cancer 89:783-792, 2000 (Pubitemid 30658577)
13. Lessnick SL, Dei Tos AP, Sorensen PH, et al: Small round cell sarcomas. Semin Oncol 36:338-346, 2009
14. de Alava E, Kawai A, Healey JH, et al: EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16:1248-1255, 1998 (Pubitemid 28175736)
15. Zucman J, Melot T, Desmaze C, et al: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 12:4481-4487, 1993 (Pubitemid 23330254)
16. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14:1245-1251, 1996
17. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group study. J Clin Oncol 27:2536-2541, 2009
18. Womer R, Krailo M, Dickman P, et al: Randomized comparison of every-two-week vs. every-three- week chemotherapy in Ewing family tumors (ESFT). J Clin Oncol 26:554s, 2008 (suppl; abstr 10504)
19. Ishii N, Hiraga H, Sawamura Y, et al: Alternative EWS-FLI1 fusion gene and MIC2 expression in peripheral and central primitive neuroectodermal tumors. Neuropathology 21:40-44, 2001 (Pubitemid 32280386)
20. Krams M, Peters J, Boeckel F, et al: In situ reverse-transcriptase polymerase chain reaction demonstration of the EWS/FLI-1 fusion transcript in Ewing's sarcomas and peripheral primitive neuroectodermal tumors. Virchows Arch 437:234-240, 2000
21. Cox DR, Oakes D: Analysis of Survival Data. Boca Raton, FL, CRC Press, 1984
22. Ginsberg JP, de Alava E, Ladanyi M, et al: EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 17:1809-1814, 1999
23. de Alava E, Panizo A, Antonescu CR, et al: Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 156:849-855, 2000 (Pubitemid 30626943)